Elicio Days Sales Outstanding vs Price To Sales Ratio Analysis

ELTX Stock

4.93 0.19 3.71%

Elicio Therapeutics financial indicator trend analysis is much more than just examining Elicio Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Elicio Therapeutics is a good investment. Please check the relationship between Elicio Therapeutics Days Sales Outstanding and its Price To Sales Ratio accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Elicio Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Elicio Stock please use our How to Invest in Elicio Therapeutics guide.

Days Sales Outstanding vs Price To Sales Ratio

Days Sales Outstanding vs Price To Sales Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Elicio Therapeutics Days Sales Outstanding account and Price To Sales Ratio. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Elicio Therapeutics' Days Sales Outstanding and Price To Sales Ratio is -0.36. Overlapping area represents the amount of variation of Days Sales Outstanding that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of Elicio Therapeutics, assuming nothing else is changed. The correlation between historical values of Elicio Therapeutics' Days Sales Outstanding and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Days Sales Outstanding of Elicio Therapeutics are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Days Sales Outstanding i.e., Elicio Therapeutics' Days Sales Outstanding and Price To Sales Ratio go up and down completely randomly.

Correlation Coefficient

-0.36

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Days Sales Outstanding

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Elicio Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Elicio Therapeutics sales, a figure that is much harder to manipulate than other Elicio Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Most indicators from Elicio Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Elicio Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Elicio Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Elicio Stock please use our How to Invest in Elicio Therapeutics guide.At this time, Elicio Therapeutics' Issuance Of Capital Stock is fairly stable compared to the past year. Enterprise Value is likely to rise to about 34.2 M in 2024, whereas Selling General Administrative is likely to drop slightly above 6.8 M in 2024.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	801K	1.1M	382K	654.8K
Interest Income	3.4K	64.8K	373K	391.7K

Depreciation And Amortization Interest Income

Elicio Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.66	0.58	0.6	0.08	-0.91	0.81	0.62	0.08	-0.92	0.97	0.72	0.94	0.93	0.94	0.72	0.44	-0.75	0.07	0.81	-0.2	0.93	0.88	0.18	0.09	0.83
Short Long Term Debt Total	0.66		0.93	0.96	-0.22	-0.84	0.54	0.99	0.7	-0.77	0.71	0.3	0.72	0.82	0.45	0.3	-0.04	-0.96	0.23	0.53	0.27	0.74	0.89	0.39	-0.15	0.58
Other Current Liab	0.58	0.93		0.98	0.01	-0.7	0.33	0.9	0.54	-0.7	0.65	0.43	0.55	0.75	0.35	0.43	0.0	-0.82	-0.04	0.36	0.22	0.62	0.73	0.14	0.1	0.38
Total Current Liabilities	0.6	0.96	0.98		-0.14	-0.74	0.34	0.95	0.58	-0.68	0.63	0.42	0.58	0.8	0.37	0.42	0.08	-0.87	0.12	0.36	0.14	0.61	0.8	0.3	-0.05	0.39
Total Stockholder Equity	0.08	-0.22	0.01	-0.14		0.03	-0.02	-0.34	-0.49	-0.24	0.16	0.34	-0.07	-0.14	0.21	0.34	-0.11	0.25	-0.98	0.2	0.13	0.04	-0.25	-0.97	0.99	-0.02
Net Tangible Assets	-0.91	-0.84	-0.7	-0.74	0.03		-0.83	-0.82	-0.42	0.96	-0.91	-0.46	-0.95	-0.91	-0.83	-0.46	-0.14	0.93	-0.15	-0.88	-0.12	-0.94	-0.97	-0.28	0.0	-0.86
Property Plant And Equipment Net	0.81	0.54	0.33	0.34	-0.02	-0.83		0.5	0.34	-0.82	0.85	0.2	0.94	0.64	0.77	0.2	-0.04	-0.69	0.17	0.94	0.24	0.93	0.78	0.23	-0.04	1.0
Current Deferred Revenue	0.62	0.99	0.9	0.95	-0.34	-0.82	0.5		0.73	-0.7	0.64	0.25	0.68	0.81	0.4	0.25	-0.01	-0.96	0.34	0.48	0.24	0.69	0.89	0.5	-0.26	0.54
Net Debt	0.08	0.7	0.54	0.58	-0.49	-0.42	0.34	0.73		-0.27	0.18	-0.46	0.33	0.24	-0.13	-0.46	-0.6	-0.67	0.42	0.24	0.71	0.35	0.49	0.51	-0.44	0.35
Retained Earnings	-0.92	-0.77	-0.7	-0.68	-0.24	0.96	-0.82	-0.7	-0.27		-0.95	-0.55	-0.92	-0.85	-0.87	-0.55	-0.11	0.84	0.12	-0.9	-0.14	-0.94	-0.88	-0.01	-0.26	-0.85
Accounts Payable	0.97	0.71	0.65	0.63	0.16	-0.91	0.85	0.64	0.18	-0.95		0.64	0.95	0.88	0.87	0.64	0.25	-0.76	-0.03	0.84	-0.01	0.97	0.87	0.09	0.18	0.87
Cash	0.72	0.3	0.43	0.42	0.34	-0.46	0.2	0.25	-0.46	-0.55	0.64		0.45	0.7	0.71	1.0	0.79	-0.28	-0.24	0.3	-0.64	0.45	0.45	-0.15	0.36	0.24
Non Current Assets Total	0.94	0.72	0.55	0.58	-0.07	-0.95	0.94	0.68	0.33	-0.92	0.95	0.45		0.86	0.87	0.45	0.19	-0.83	0.22	0.9	0.05	0.98	0.93	0.31	-0.07	0.96
Non Currrent Assets Other	0.93	0.82	0.75	0.8	-0.14	-0.91	0.64	0.81	0.24	-0.85	0.88	0.7	0.86		0.81	0.7	0.48	-0.86	0.25	0.64	-0.24	0.84	0.94	0.38	-0.1	0.68
Other Assets	0.94	0.45	0.35	0.37	0.21	-0.83	0.77	0.4	-0.13	-0.87	0.87	0.71	0.87	0.81		0.71	0.48	-0.59	-0.03	0.86	-0.27	0.83	0.75	0.04	0.2	0.79
Cash And Short Term Investments	0.72	0.3	0.43	0.42	0.34	-0.46	0.2	0.25	-0.46	-0.55	0.64	1.0	0.45	0.7	0.71		0.79	-0.28	-0.24	0.3	-0.64	0.45	0.45	-0.15	0.36	0.24
Net Receivables	0.44	-0.04	0.0	0.08	-0.11	-0.14	-0.04	-0.01	-0.6	-0.11	0.25	0.79	0.19	0.48	0.48	0.79		0.01	0.21	-0.03	-0.97	0.1	0.22	0.22	-0.12	-0.02
Common Stock Shares Outstanding	-0.75	-0.96	-0.82	-0.87	0.25	0.93	-0.69	-0.96	-0.67	0.84	-0.76	-0.28	-0.83	-0.86	-0.59	-0.28	0.01		-0.3	-0.7	-0.25	-0.82	-0.96	-0.45	0.19	-0.72
Non Current Liabilities Total	0.07	0.23	-0.04	0.12	-0.98	-0.15	0.17	0.34	0.42	0.12	-0.03	-0.24	0.22	0.25	-0.03	-0.24	0.21	-0.3		-0.05	-0.2	0.09	0.35	0.98	-0.99	0.17
Capital Lease Obligations	0.81	0.53	0.36	0.36	0.2	-0.88	0.94	0.48	0.24	-0.9	0.84	0.3	0.9	0.64	0.86	0.3	-0.03	-0.7	-0.05		0.25	0.9	0.75	0.02	0.18	0.94
Inventory	-0.2	0.27	0.22	0.14	0.13	-0.12	0.24	0.24	0.71	-0.14	-0.01	-0.64	0.05	-0.24	-0.27	-0.64	-0.97	-0.25	-0.2	0.25		0.14	0.03	-0.17	0.14	0.22
Other Current Assets	0.93	0.74	0.62	0.61	0.04	-0.94	0.93	0.69	0.35	-0.94	0.97	0.45	0.98	0.84	0.83	0.45	0.1	-0.82	0.09	0.9	0.14		0.9	0.2	0.05	0.95
Other Stockholder Equity	0.88	0.89	0.73	0.8	-0.25	-0.97	0.78	0.89	0.49	-0.88	0.87	0.45	0.93	0.94	0.75	0.45	0.22	-0.96	0.35	0.75	0.03	0.9		0.48	-0.22	0.81
Total Liab	0.18	0.39	0.14	0.3	-0.97	-0.28	0.23	0.5	0.51	-0.01	0.09	-0.15	0.31	0.38	0.04	-0.15	0.22	-0.45	0.98	0.02	-0.17	0.2	0.48		-0.96	0.23
Net Invested Capital	0.09	-0.15	0.1	-0.05	0.99	0.0	-0.04	-0.26	-0.44	-0.26	0.18	0.36	-0.07	-0.1	0.2	0.36	-0.12	0.19	-0.99	0.18	0.14	0.05	-0.22	-0.96		-0.04
Property Plant And Equipment Gross	0.83	0.58	0.38	0.39	-0.02	-0.86	1.0	0.54	0.35	-0.85	0.87	0.24	0.96	0.68	0.79	0.24	-0.02	-0.72	0.17	0.94	0.22	0.95	0.81	0.23	-0.04

Click cells to compare fundamentals

Elicio Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Elicio Stock Analysis

When running Elicio Therapeutics' price analysis, check to measure Elicio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elicio Therapeutics is operating at the current time. Most of Elicio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Elicio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elicio Therapeutics' price. Additionally, you may evaluate how the addition of Elicio Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Elicio Days Sales Outstanding vs Price To Sales Ratio Analysis

Days Sales Outstanding vs Price To Sales Ratio

Days Sales Outstanding vs Price To Sales Ratio Correlation Analysis

Correlation Coefficient

Days Sales Outstanding

Price To Sales Ratio

Elicio Therapeutics fundamental ratios Correlations

Elicio Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Elicio Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Current Deferred Revenue	+ 0.99	Short Long Term Debt Total
Net Invested Capital	+ 0.99	Total Stockholder Equity
Total Current Liabilities	+ 0.98	Other Current Liab
Other Current Assets	+ 0.98	Non Current Assets Total

Net Invested Capital	- 0.99	Non Current Liabilities Total
Non Current Liabilities Total	- 0.98	Total Stockholder Equity
Inventory	- 0.97	Net Receivables
Other Stockholder Equity	- 0.97	Net Tangible Assets
Total Liab	- 0.97	Total Stockholder Equity
Net Invested Capital	- 0.96	Total Liab